Current and emerging concepts on the role of peripheral signals in the control of food intake and development of obesity

British Journal of Nutrition

Volumn 108, Issue 5, 2012, Pages 778-793

  Duca, F A ^a,b   Covasa, M ^a,c  

^a UMR1319 MICALIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Cholecystokinin; Glucagon like peptide; Microbiota; Peptide YY; Satiation; Taste

Indexed keywords

CHOLECYSTOKININ; DOPAMINE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; LEPTIN; PEPTIDE YY; PRAMLINTIDE;

ARCUATE NUCLEUS; BODY WEIGHT; DIETARY INTAKE; ENERGY METABOLISM; FOOD INTAKE; HUMAN; INTESTINE ABSORPTION; INTESTINE FLORA; MOLECULAR PATHOLOGY; NONHUMAN; OBESITY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SATIETY; SIGNAL TRANSDUCTION; WEIGHT CONTROL; BRAIN; DIGESTIVE FUNCTION; FEEDING BEHAVIOR; HOMEOSTASIS; PATHOPHYSIOLOGY; PHYSIOLOGY;

BRAIN; DIGESTIVE SYSTEM PHYSIOLOGICAL PHENOMENA; ENERGY METABOLISM; FEEDING BEHAVIOR; HOMEOSTASIS; HUMANS; OBESITY; SIGNAL TRANSDUCTION;

EID: 84871888268     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114512000529     Document Type: Review

References (232)

1. Berthoud HR (2005) Brain, appetite and obesity. Physiol Behav 85, 1-2.
2. Woods SC (2005) Signals that influence food intake and body weight. Physiol Behav 86, 709-716.
3. Blundell JE (2006) Perspective on the central control of appetite. Obesity (Silver Spring) 14, Suppl. 4, 160S-163S.
4. Woods SC (2009) The control of food intake: behavioral versus molecular perspectives. Cell Metab 9, 489-498.
5. Neary MT & Batterham RL (2009) Gut hormones: implications for the treatment of obesity. Pharmacol Ther 124, 44-56.
6. Faulconbridge LF, Cummings DE, Kaplan JM, et al. (2003) Hyperphagic effects of brainstem ghrelin administration. Diabetes 52, 2260-2265.
7. Grill HJ (2010) Leptin and the systems neuroscience of meal size control. Front Neuroendocrinol 31, 61-78.
8. Sexton PM, Paxinos G, Kenney MA, et al. (1994) In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience 62, 553-567.
9. Grill HJ (2006) Distributed neural control of energy balance: contributions from hindbrain and hypothalamus. Obesity (Silver Spring) 14, Suppl. 5, 216S-221S.
10. Banks WA, Kastin AJ, Huang W, et al. (1996) Leptin enters the brain by a saturable system independent of insulin. Peptides 17, 305-311.
11. Burguera B & Couce ME (2001) Leptin access into the brain: a saturated transport mechanism in obesity. Physiol Behav 74, 717-720.
12. Moran TH (2009) Hypothalamic nutrient sensing and energy balance. Forum Nutr 63, 94-101.
13. Munzberg H (2008) Differential leptin access into the brain-a hierarchical organization of hypothalamic leptin target sites Physiol Behav 94, 664-669.
14. Blevins JE & Baskin DG (2010) Hypothalamic-brainstem circuits controlling eating. Forum Nutr 63, 133-140.
15. Langhans W & Geary N (2010) Overview of the physiological control of eating. Forum Nutr 63, 9-53.
16. Lenard NR & Berthoud HR (2008) Central and peripheral regulation of food intake and physical activity: pathways and genes. Obesity (Silver Spring) 16, Suppl. 3, S11-S22.
17. Rolls BJ (2003) The supersizing of America: portion size and the obesity epidemic. Nutr Today 38, 42-53.
18. Bachmanov AA & Beauchamp GK (2007) Taste receptor genes. Annu Rev Nutr 27, 389-414.
19. Berthoud H-R (2002) Multiple neural systems controlling food intake and body weight. Neurosci Biobehav Rev 26, 393-428.
20. Chandrashekar J, Mueller KL, Hoon MA, et al. (2000) T2Rs function as bitter taste receptors. Cell 100, 703-711.
21. Li X, Staszewski L, Xu H, et al. (2002) Human receptors for sweet and umami taste. Proc Natl Acad Sci USA 99, 4692-4696.
22. Nelson G, Hoon MA, Chandrashekar J, et al. (2001) Mammalian sweet taste receptors. Cell 106, 381-390.
23. Zhao GQ, Zhang Y, Hoon MA, et al. (2003) The receptors for mammalian sweet and umami taste. Cell 115, 255-266.
24. Inoue M, Glendinning JI, Theodorides ML, et al. (2007) Allelic variation of the Tas1r3 taste receptor gene selectively affects taste responses to sweeteners: evidence from 129.B6-Tas1r3 congenic mice. Physiol Genomics 32, 82-94.
25. Eny KM, Wolever TM, Corey PN, et al. (2010) Genetic variation in TAS1R2 (Ile191Val) is associated with consumption of sugars in overweight and obese individuals in 2 distinct populations. Am J Clin Nutr 92, 1501-1510.
26. Donaldson LF, Bennett L, Baic S, et al. (2009) Taste and weight: is there a link Am J Clin Nutr 90, 800S-803S.
27. Bartoshuk LM, Duffy VB, Hayes JE, et al. (2006) Psychophysics of sweet and fat perception in obesity: problems, solutions and new perspectives. Philos Trans R Soc Lond B Biol Sci 361, 1137-1148.
28. Grinker J (1978) Obesity and sweet taste. Am J Clin Nutr 31, 1078-1087.
29. Grinker J & Hirsch J (1972) Metabolic and behavioural correlates of obesity. Ciba Found Symp 8, 349-369.
30. De Jonghe BC, Hajnal A & Covasa M (2005) Increased oral and decreased intestinal sensitivity to sucrose in obese, prediabetic CCK-A receptor-deficient OLETF rats. Am J Physiol Regul Integr Comp Physiol 288, R292-R300.
31. Shin AC & Berthoud HR (2011) Food reward functions as affected by obesity and bariatric surgery. Int J Obes (Lond) 35, Suppl. 3, S40-S44.
32. Mattes RD (2011) Oral fatty acid signaling and intestinal lipid processing: support and supposition. Physiol Behav 105, 27-35.
33. Fukuwatari T, Kawada T, Tsuruta M, et al. (1997) Expression of the putative membrane fatty acid transporter (FAT) in taste buds of the circumvallate papillae in rats. FEBS Lett 414, 461-464.
34. Gilbertson TA, Fontenot DT, Liu L, et al. (1997) Fatty acid modulation of K \+ channels in taste receptor cells: gustatory cues for dietary fat. Am J Physiol 272, C1203-C1210.
35. Laugerette F, Passilly-Degrace P, Patris B, et al. (2005) CD36 involvement in orosensory detection of dietary lipids, spontaneous fat preference, and digestive secretions. J Clin Invest 115, 3177-3184.
36. Sclafani A, Ackroff K & Abumrad NA (2007) CD36 gene deletion reduces fat preference and intake but not postoral fat conditioning in mice. Am J Physiol Regul Integr Comp Physiol 293, R1823-R1832.
37. Choquet H, Labrune Y, De Graeve F, et al. (2010) Lack of association of CD36 SNPs with early onset obesity: a meta-analysis in 9,973 European subjects. Obesity 19, 833-839.
38. Zhang XJ, Zhou LH, Ban X, et al. (2011) Decreased expression of CD36 in circumvallate taste buds of high-fat diet induced obese rats. Acta Histochem 113, 663-667.
39. Mattes RD (2009) Is there a fatty acid taste Annu Rev Nutr 29, 305-327.
40. Cartoni C, Yasumatsu K, Ohkuri T, et al. (2010) Taste preference for fatty acids is mediated by GPR40 and GPR120. J Neurosci 30, 8376-8382.
41. Stewart JE, Feinle-Bisset C, Golding M, et al. (2010) Oral sensitivity to fatty acids, food consumption and BMI in human subjects. Br J Nutr 104, 145-152.
42. Tanaka T, Katsuma S, Adachi T, et al. (2008) Free fatty acids induce cholecystokinin secretion through GPR120. Naunyn Schmiedebergs Arch Pharmacol 377, 523-527.
43. Margolskee RF, Dyer J, Kokrashvili Z, et al. (2007) T1R3 and gustducin in gut sense sugars to regulate expression of Na \+-glucose cotransporter 1. Proc Natl Acad Sci USA 104, 15075-15080.
44. Liou AP, Lu X, Sei Y, et al. (2010) The G-protein-coupled receptor GPR40 directly mediates long-chain fatty acidinduced secretion of cholecystokinin. Gastroenterology 140, 903-912.
45. Hass N, Schwarzenbacher K & Breer H (2010) T1R3 is expressed in brush cells and ghrelin-producing cells of murine stomach. Cell Tissue Res 339, 493-504.
46. Bezencon C, le Coutre J & Damak S (2007) Taste-signaling proteins are coexpressed in solitary intestinal epithelial cells. Chem Senses 32, 41-49.
47. Sutherland K, Young RL, Cooper NJ, et al. (2007) Phenotypic characterization of taste cells of the mouse small intestine. Am J Physiol Gastrointest Liver Physiol 292, G1420-G1428.
48. Rozengurt N, Wu SV, Chen MC, et al. (2006) Colocalization of the alpha-subunit of gustducin with PYY and GLP-1 in L cells of human colon. Am J Physiol Gastrointest Liver Physiol 291, G792-G802.
49. Jang HJ, Kokrashvili Z, Theodorakis MJ, et al. (2007) Gutexpressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci USA 104, 15069-15074.
50. Young RL, Sutherland K, Pezos N, et al. (2009) Expression of taste molecules in the upper gastrointestinal tract in humans with and without type 2 diabetes. Gut 58, 337-346.
51. Dyer J, Salmon KS, Zibrik L, et al. (2005) Expression of sweet taste receptors of the T1R family in the intestinal tract and enteroendocrine cells. Biochem Soc Trans 33, 302-305.
52. Hirasawa A, Tsumaya K, Awaji T, et al. (2005) Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 11, 90-94.
53. Tanaka T, Yano T, Adachi T, et al. (2008) Cloning and characterization of the rat free fatty acid receptor GPR120: in vivo effect of the natural ligand on GLP-1 secretion and proliferation of pancreatic beta cells. Naunyn Schmiedebergs Arch Pharmacol 377, 515-522.
54. Steinert RE, Frey F, Topfer A, et al. (2011) Effects of carbohydrate sugars and artificial sweeteners on appetite and the secretion of gastrointestinal satiety peptides. Br J Nutr 105, 1320-1328.
55. Phillips RJ & Powley TL (2000) Tension and stretch receptors in gastrointestinal smooth muscle: re-evaluating vagal mechanoreceptor electrophysiology. Brain Res Brain Res Rev 34, 1-26.
56. Tschop M, Smiley DL & Heiman ML (2000) Ghrelin induces adiposity in rodents. Nature 407, 908-913.
57. Wren AM, Seal LJ, Cohen MA, et al. (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86, 5992.
58. Wren AM, Small CJ, Abbott CR, et al. (2001) Ghrelin causes hyperphagia and obesity in rats. Diabetes 50, 2540-2547.
59. Date Y, Kojima M, Hosoda H, et al. (2000) Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141, 4255-4261.
60. Kojima M, Hosoda H, Date Y, et al. (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656-660.
61. Cummings DE, Frayo RS, Marmonier C, et al. (2004) Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time-and food-related cues. Am J Physiol Endocrinol Metab 287, E297-E304.
62. Cummings DE, Purnell JQ, Frayo RS, et al. (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50, 1714-1719.
63. Frecka JM & Mattes RD (2008) Possible entrainment of ghrelin to habitual meal patterns in humans. Am J Physiol Gastrointest Liver Physiol 294, G699-G707.
64. Hosoda H, Kojima M, Mizushima T, et al. (2003) Structural divergence of human ghrelin. Identification of multiple ghrelin-derived molecules produced by post-translational processing. J Biol Chem 278, 64-70.
65. Yang J, Brown MS, Liang G, et al. (2008) Identification of the acyltransferase that octanoylates ghrelin, an appetitestimulating peptide hormone. Cell 132, 387-396.
66. Tamura H, Kamegai J, Shimizu T, et al. (2002) Ghrelin stimulates GH but not food intake in arcuate nucleus ablated rats. Endocrinology 143, 3268-3275.
67. Nakazato M, Murakami N, Date Y, et al. (2001) A role for ghrelin in the central regulation of feeding. Nature 409, 194-198.
68. Chen HY, Trumbauer ME, Chen AS, et al. (2004) Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology 145, 2607-2612.
69. le Roux CW, Neary NM, Halsey TJ, et al. (2005) Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy. J Clin Endocrinol Metab 90, 4521-4524.
70. Date Y, Murakami N, Toshinai K, et al. (2002) The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123, 1120-1128.
71. de Lartigue G, Dimaline R, Varro A, et al. (2007) Cocaineand amphetamine-regulated transcript: stimulation of expression in rat vagal afferent neurons by cholecystokinin and suppression by ghrelin. J Neurosci 27, 2876-2882.
72. Burdyga G, Varro A, Dimaline R, et al. (2006) Ghrelin receptors in rat and human nodose ganglia: putative role in regulating CB-1 and MCH receptor abundance. Am J Physiol Gastrointest Liver Physiol 290, G1289-G1297.
73. Sun Y, Asnicar M, Saha PK, et al. (2006) Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. Cell Metab 3, 379-386.
74. Wortley KE, del Rincon JP, Murray JD, et al. (2005) Absence of ghrelin protects against early-onset obesity. J Clin Invest 115, 3573-3578.
75. Gardiner JV, Campbell D, Patterson M, et al. (2010) The hyperphagic effect of ghrelin is inhibited in mice by a diet high in fat. Gastroenterology 138, 2468-2476, 2476 e1.
76. Kirchner H, Gutierrez JA, Solenberg PJ, et al. (2009) GOAT links dietary lipids with the endocrine control of energy balance. Nat Med 15, 741-745.
77. Asakawa A, Inui A, Kaga T, et al. (2003) Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 52, 947-952.
78. Shearman LP, Wang SP, Helmling S, et al. (2006) Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. Endocrinology 147, 1517-1526.
79. Varela L, Vazquez MJ, Cordido F, et al. (2011) Ghrelin and lipid metabolism: key partners in energy balance. J Mol Endocrinol 46, R43-R63.
80. Rodriguez A, Gomez-Ambrosi J, Catalan V, et al. (2009) Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Int J Obes (Lond) 33, 541-552.
81. Cummings DE, Clement K, Purnell JQ, et al. (2002) Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med 8, 643-644.
82. Feigerlova E, Diene G, Conte-Auriol F, et al. (2008) Hyperghrelinemia precedes obesity in Prader-Willi syndrome. J Clin Endocrinol Metab 93, 2800-2805.
83. Goldstone AP, Thomas EL, Brynes AE, et al. (2004) Elevated fasting plasma ghrelin in Prader-Willi syndrome adults is not solely explained by their reduced visceral adiposity and insulin resistance. J Clin Endocrinol Metab 89, 1718-1726.
84. Tschop M, Weyer C, Tataranni PA, et al. (2001) Circulating ghrelin levels are decreased in human obesity. Diabetes 50, 707-709.
85. le Roux CW, Patterson M, Vincent RP, et al. (2005) Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects. J Clin Endocrinol Metab 90, 1068-1071.
86. Beckman LM, Beckman TR & Earthman CP (2010) Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review. J Am Diet Assoc 110, 571-584.
87. Kojima M & Kangawa K (2005) Ghrelin: structure and function. Physiol Rev 85, 495-522.
88. Wang Y & Liu J (2010) Combination of bypassing stomach and vagus dissection in high-fat diet-induced obese rats-a long-term investigation. Obes Surg 20, 375-379.
89. Vizcarra JA, Kirby JD, Kim SK, et al. (2007) Active immunization against ghrelin decreases weight gain and alters plasma concentrations of growth hormone in growing pigs. Domest Anim Endocrinol 33, 176-189.
90. Gualillo O, Lago F & Dieguez C (2008) Introducing GOAT: a target for obesity and anti-diabetic drugs Trends Pharmacol Sci 29, 398-401.
91. Zorrilla EP, Iwasaki S, Moss JA, et al. (2006) Vaccination against weight gain. Proc Natl Acad Sci USA 103, 13226-13231.
92. Cytos Biotechnology. (2006) Phase I/IIa clinical trial with obese individuals shows no effect of CYT009-GhrQb on weight loss Cytos Biotechnology: Media Release [serial on the Internet]. http://www.cytos.com/doc/Cytos-Press-E- 061107.pdf
93. Barnett BP, Hwang Y, Taylor MS, et al. (2010) Glucose and weight control in mice with a designed ghrelin O-acyltransferase inhibitor. Science 330, 1689-1692.
94. Kobelt P, Helmling S, Stengel A, et al. (2006) Anti-ghrelin Spiegelmer NOX-B11 inhibits neurostimulatory and orexigenic effects of peripheral ghrelin in rats. Gut 55, 788-792.
95. Moran TH & Kinzig KP (2004) Gastrointestinal satiety signals II. Cholecystokinin. Am J Physiol Gastrointest Liver Physiol 286, G183-G188.
96. Ritter RC, Covasa M & Matson CA (1999) Cholecystokinin: proofs and prospects for involvement in control of food intake and body weight. Neuropeptides 33, 387-399.
97. Kissileff HR, Carretta JC, Geliebter A, et al. (2003) Cholecystokinin and stomach distension combine to reduce food intake in humans. Am J Physiol Regul Integr Comp Physiol 285, R992-R998.
98. Asarian L & Geary N (2007) Estradiol enhances cholecystokinin- dependent lipid-induced satiation and activates estrogen receptor-{alpha}- expressing cells in the nucleus tractus solitarius of ovariectomized rats. Endocrinology 148, 5656-5666.
99. Hayes MR & Covasa M (2005) CCK and 5-HT act synergistically to suppress food intake through simultaneous activation of CCK-1 and 5-HT3 receptors. Peptides 26, 2322-2330.
100. Hayes MR, Savastano DM & Covasa M (2004) Cholecystokinin-induced satiety is mediated through interdependent cooperation of CCK-A and 5-HT3 receptors. Physiol Behav 82, 663-669.
101. Peters JH, Simasko SM & Ritter RC (2006) Modulation of vagal afferent excitation and reduction of food intake by leptin and cholecystokinin. Physiol Behav 89, 477-485.
102. Degen L, Drewe J, Piccoli F, et al. (2007) Effect of CCK-1 receptor blockade on ghrelin and PYY secretion in men. Am J Physiol Regul Integr Comp Physiol 292, R1391-R1399.
103. Brennan IM, Little TJ, Feltrin KL, et al. (2008) Dose-dependent effects of cholecystokinin-8 on antropyloroduodenal motility, gastrointestinal hormones, appetite, and energy intake in healthy men. Am J Physiol Endocrinol Metab 295, E1487-E1494.
104. Lo CM, Zhang DM, Pearson K, et al. (2007) Interaction of apolipoprotein AIV with cholecystokinin on the control of food intake. Am J Physiol Regul Integr Comp Physiol 293, R1490-R14R4.
105. Funakoshi A, Miyasaka K, Matsumoto H, et al. (2000) Gene structure of human cholecystokinin (CCK) type-A receptor: body fat content is related to CCK type-A receptor gene promoter polymorphism. FEBS Lett 466, 264-266.
106. de Krom M, van der Schouw YT, Hendriks J, et al. (2007) Common genetic variations in CCK, leptin, and leptin receptor genes are associated with specific human eating patterns. Diabetes 56, 276-280.
107. Zwirska-Korczala K, Konturek SJ, Sodowski M, et al. (2007) Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome. J Physiol Pharmacol 58, Suppl. 1, 13-35.
108. French SJ, Murray B, Rumsey RD, et al. (1993) Preliminary studies on the gastrointestinal responses to fatty meals in obese people. Int J Obes Relat Metab Disord 17, 295-300.
109. Glatzle J, Raybould HE, Kueper MA, et al. (2008) Cholecystokinin-58 is more potent in inhibiting food intake than cholecystokinin-8 in rats. Nutr Neurosci 11, 69-74.
110. Naslund E, Gryback P, Hellstrom PM, et al. (1997) Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 21, 387-392.
111. Roses AD (2004) Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 5, 645-656.
112. Lateef DM, Washington MC & Sayegh AI (2011) The short term satiety peptide cholecystokinin reduces meal size and prolongs intermeal interval. Peptides 32, 1289-1295.
113. Matson CA, Reid DF, Cannon TA, et al. (2000) Cholecystokinin and leptin act synergistically to reduce body weight. Am J Physiol Regul Integr Comp Physiol 278, R882-R890.
114. Matson CA, Reid DF & Ritter RC (2002) Daily CCK injection enhances reduction of body weight by chronic intracerebroventricular leptin infusion. Am J Physiol Regul Integr Comp Physiol 282, R1368-R1373.
115. Emond M, Schwartz GJ, Ladenheim EE, et al. (1999) Central leptin modulates behavioral and neural responsivity to CCK. Am J Physiol 276, R1545-R1549.
116. Bhavsar S, Watkins J & Young A (1998) Synergy between amylin and cholecystokinin for inhibition of food intake in mice. Physiol Behav 64, 557-561.
117. Matson CA & Ritter RC (1999) Long-term CCK-leptin synergy suggests a role for CCK in the regulation of body weight. Am J Physiol Regul Integr Comp Physiol 276, R1038-R1045.
118. Holst JJ (2010) Glucagon and glucagon-like peptides 1 and Results Probl Cell Differ 50, 121-135
119. Dube PE & Brubaker PL (2004) Nutrient, neural and endocrine control of glucagon-like peptide secretion. Horm Metab Res 36, 755-760.
120. Holst JJ, Orskov C, Nielsen OV, et al. (1987) Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 211, 169-174.
121. Mojsov S, Weir GC & Habener JF (1987) Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79, 616-619.
122. D'Alessio D, Lu W, Sun W, et al. (2007) Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system. Am J Physiol Regul Integr Comp Physiol 293, R2163-R2169.
123. Mentlein R, Gallwitz B & Schmidt WE (1993) Dipeptidylpeptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214, 829-835.
124. Deacon CF, Pridal L, Klarskov L, et al. (1996) Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 271, E458-E464.
125. Imeryuz N, Yegen BC, Bozkurt A, et al. (1997) Glucagonlike peptide-1 inhibits gastric emptying via vagal afferentmediated central mechanisms. Am J Physiol 273, G920-G927.
126. Little TJ, Pilichiewicz AN, Russo A, et al. (2006) Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab 91, 1916-1923.
127. Shiiya T, Nakazato M, Mizuta M, et al. (2002) Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 87, 240-244.
128. Tolessa T, Gutniak M, Holst JJ, et al. (1998) Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 43, 2284-2290.
129. Donahey JC, van Dijk G, Woods SC, et al. (1998) Intraventricular GLP-1 reduces short-but not long-term food intake or body weight in lean and obese rats. Brain Res 779, 75-83.
130. Tang-Christensen M, Larsen PJ, Goke R, et al. (1996) Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 271, R848-R856.
131. Turton MD, O'Shea D, Gunn I, et al. (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69-72.
132. Larsen PJ & Holst JJ (2005) Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regul Pept 128, 97-107.
133. Rodriquez de Fonseca F, Navarro M, Alvarez E, et al. (2000) Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 49, 709-717.
134. Abbott CR, Monteiro M, Small CJ, et al. (2005) The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044, 127-131.
135. Williams DL, Baskin DG & Schwartz MW (2009) Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 150, 1680-1687.
136. Hayes MR, Leichner TM, Zhao S, et al. (2011) Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation. Cell Metab 13, 320-330.
137. Kanoski SE, Fortin SM, Arnold M, et al. (2011) Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 152, 3103-3112.
138. Ruttimann EB, Arnold M, Hillebrand JJ, et al. (2009) Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 150, 1174-1181.
139. Zhang J & Ritter RC (2011) Circulating GLP-1 and CCK-8 reduce food intake by capsaicin-insensitive, non-vagal mechanisms. Am J Physiol Regul Integr Comp Physiol 302, R264-R273.
140. Ruttimann EB, Arnold M, Geary N, et al. (2010) GLP-1 antagonism with exendin (9-39) fails to increase spontaneous meal size in rats. Physiol Behav 100, 291-296.
141. Orskov C, Wettergren A & Holst JJ (1996) Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 31, 665-670.
142. Ma X, Bruning J & Ashcroft FM (2007) Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons. J Neurosci 27, 7125-7129.
143. Seo S, Ju S, Chung H, et al. (2008) Acute effects of glucagon-like peptide-1 on hypothalamic neuropeptide and AMP activated kinase expression in fasted rats. Endocr J 55, 867-874.
144. Asarian L (2009) Loss of cholecystokinin and glucagon-like peptide-1-induced satiation in mice lacking serotonin 2C receptors. Am J Physiol Regul Integr Comp Physiol 296, R51-R56.
145. Neary NM, Small CJ, Druce MR, et al. (2005) Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 146, 5120-5127.
146. Bojanowska E & Nowak A (2007) Interactions between leptin and exendin-4, a glucagon-like peptide-1 agonist, in the regulation of food intake in the rat. J Physiol Pharmacol 58, 349-360.
147. Nowak A & Bojanowska E (2008) Effects of peripheral or central GLP-1 receptor blockade on leptin-induced suppression of appetite. J Physiol Pharmacol 59, 501-510.
148. Naslund E, Gryback P, Backman L, et al. (1998) Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying. Dig Dis Sci 43, 945-952.
149. Rask E, Olsson T, Soderberg S, et al. (2001) Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 24, 1640-1645.
150. Williams DL, Hyvarinen N, Lilly N, et al. (2011) Maintenance on a high-fat diet impairs the anorexic response to glucagon-like-peptide-1 receptor activation. Physiol Behav 103, 557-564.
151. Hayes MR, Kanoski SE, Alhadeff AL, et al. (2011) Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats. Obesity (Silver Spring) 19, 1342-1349.
152. Baggio LL, Huang Q, Brown TJ, et al. (2004) Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127, 546-558.
153. Berthoud HR, Shin AC & Zheng H (2011) Obesity surgery and gut-brain communication. Physiol Behav 105, 106-119.
154. Astrup A, Rossner S, Van Gaal L, et al. (2009) Effects of liraglutide in the treatment of obesity: a randomised, doubleblind, placebo-controlled study. Lancet 374, 1606-1616.
155. Nayak UA, Govindan J, Baskar V, et al. (2010) Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM 103, 687-694.
156. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, et al. (1985) Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89, 1070-1077.
157. Eberlein GA, Eysselein VE, Schaeffer M, et al. (1989) A new molecular form of PYY: structural characterization of human PYY(3-36) and PYY(1-36). Peptides 10, 797-803.
158. Acuna-Goycolea C & van den Pol AN (2005) Peptide YY(3-36) inhibits both anorexigenic proopiomelanocortin and orexigenic neuropeptide Y neurons: implications for hypothalamic regulation of energy homeostasis. J Neurosci 25, 10510-10519.
159. Batterham RL, Cowley MA, Small CJ, et al. (2002) Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418, 650-654.
160. Challis BG, Pinnock SB, Coll AP, et al. (2003) Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Commun 311, 915-919.
161. Challis BG, Coll AP, Yeo GS, et al. (2004) Mice lacking proopiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36). Proc Natl Acad Sci USA 101, 4695-4700.
162. Halatchev IG, Ellacott KL, Fan W, et al. (2004) Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology 145, 2585-2590.
163. Koda S, Date Y, Murakami N, et al. (2005) The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology 146, 2369-2375.
164. Moran TH & Dailey MJ (2011) Intestinal feedback signaling and satiety. Physiol Behav 105, 77-81.
165. Guo Y, Ma L, Enriori PJ, et al. (2006) Physiological evidence for the involvement of peptide YY in the regulation of energy homeostasis in humans. Obesity (Silver Spring) 14, 1562-1570.
166. le Roux CW, Batterham RL, Aylwin SJ, et al. (2006) Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 147, 3-8.
167. Yang N, Wang C, Xu M, et al. (2005) Interaction of dietary composition and PYY gene expression in diet-induced obesity in rats. J Huazhong Univ Sci Technolog Med Sci 25, 243-246.
168. Batterham RL, Cohen MA, Ellis SM, et al. (2003) Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349, 941-948.
169. Chandarana K, Gelegen C, Karra E, et al. (2011) Diet and gastrointestinal bypass-induced weight loss: the roles of ghrelin and peptide YY. Diabetes 60, 810-818.
170. Shin AC, Zheng H, Townsend RL, et al. (2010) Mealinduced hormone responses in a rat model of Roux-en-Y gastric bypass surgery. Endocrinology 151, 1588-1597.
171. Batterham RL, Heffron H, Kapoor S, et al. (2006) Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 4, 223-233.
172. Gantz I, Erondu N, Mallick M, et al. (2007) Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 92, 1754-1757.
173. Reidelberger RD, Haver AC, Apenteng BA, et al. (2011) Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats. Obesity (Silver Spring) 19, 121-127.
174. Field BCT, Wren AM, Peters V, et al. (2010) PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 59, 1635-1639.
175. Wynne K & Bloom SR (2006) The role of oxyntomodulin and peptide tyrosine-tyrosine (PYY) in appetite control. Nat Clin Pract Endocrinol Metab 2, 612-620.
176. Wynne K, Park AJ, Small CJ, et al. (2006) Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond) 30, 1729-1736.
177. Liu YL, Ford HE, Druce MR, et al. (2010) Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents. Int J Obes (Lond) 34, 1715-1725.
178. Roth JD, Roland BL, Cole RL, et al. (2008) Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA 105, 7257-7262.
179. Trevaskis JL, Coffey T, Cole R, et al. (2008) Amylinmediated restoration of leptin responsiveness in dietinduced obesity: magnitude and mechanisms. Endocrinology 149, 5679-5687.
180. Trevaskis JL, Turek VF, Griffin PS, et al. (2010) Multi-hormonal weight loss combinations in diet-induced obese rats: therapeutic potential of cholecystokinin Physiol Behav 100, 187-195.
181. Covasa M (2010) Deficits in gastrointestinal responses controlling food intake and body weight. Am J Physiol Regul Integr Comp Physiol 299, R1423-R1439.
182. Swartz TD, Savastano DM & Covasa M (2010) Reduced sensitivity to cholecystokinin in male rats fed a high-fat diet is reversible. J Nutr 140, 1698-1703.
183. Covasa M & Ritter RC (1998) Rats maintained on high-fat diets exhibit reduced satiety in response to CCK and bombesin. Peptides 19, 1407-1415.
184. Savastano DM & Covasa M (2005) Adaptation to a high-fat diet leads to hyperphagia and diminished sensitivity to cholecystokinin in rats. J Nutr 135, 1953-1959.
185. Boyd KA, O'Donovan DG, Doran S, et al. (2003) High-fat diet effects on gut motility, hormone, and appetite responses to duodenal lipid in healthy men. Am J Physiol Gastrointest Liver Physiol 284, G188-G196.
186. Bray GA, Paeratakul S & Popkin BM (2004) Dietary fat and obesity: a review of animal, clinical and epidemiological studies. Physiol Behav 83, 549-555.
187. Wortley KE, Chang G-Q, Davydova Z, et al. (2003) Orexin gene expression is increased during states of hypertriglyceridemia. Am J Physiol Regul Integr Comp Physiol 284, R1454-R1465.
188. Leibowitz SF, Akabayashi A & Wang J (1998) Obesity on a high-fat diet: role of hypothalamic galanin in neurons of the anterior paraventricular nucleus projecting to the median eminence. J Neurosci 18, 2709-2719.
189. Wang H, Storlien LH & Huang X-F (2002) Effects of dietary fat types on body fatness, leptin, and ARC leptin receptor, NPY, and AgRP mRNA expression. Am J Physiol Endocrinol Metab 282, E1352-E1359.
190. Huang XF, Xin X, McLennan P, et al. (2004) Role of fat amount and type in ameliorating diet-induced obesity: insights at the level of hypothalamic arcuate nucleus leptin receptor, neuropeptide Y and pro-opiomelanocortin mRNA
191. Ley RE, Turnbaugh PJ, Klein S, et al. (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022-1023.
192. Turnbaugh PJ, Backhed F, Fulton L, et al. (2008) Dietinduced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 3, 213-223.
193. Turnbaugh PJ, Ridaura VK, Faith JJ, et al. (2009) The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 1, 6ra14.
194. Backhed F, Ding H, Wang T, et al. (2004) The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 101, 15718-15723.
195. Backhed F, Manchester JK, Semenkovich CF, et al. (2007) Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 104, 979-984.
196. Rabot S, Membrez M, Bruneau A, et al. (2010) Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB J 24, 4948-4959.
197. Turnbaugh PJ, Ley RE, Mahowald MA, et al. (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027-1031.
198. de La Serre CB, Ellis CL, Lee J, et al. (2010) Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol 299, G440-G448.
199. Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, et al. (2009) High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 137, 1716-1724, e1-2.
200. Mozes S, Bujnakova D, Sefcikova Z, et al. (2008) Developmental changes of gut microflora and enzyme activity in rat pups exposed to fat-rich diet. Obesity (Silver Spring) 16, 2610-2615.
201. Musso G, Gambino R & Cassader M (2010) Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. Curr Opin Lipidol 21, 76-83.
202. Samuel BS, Shaito A, Motoike T, et al. (2008) Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci USA 105, 16767-16772.
203. Dewulf EM, Cani PD, Neyrinck AM, et al. (2011) Inulin-type fructans with prebiotic properties counteract GPR43 overexpression and PPAR-g-related adipogenesis in the white adipose tissue of high-fat diet-fed mice. J Nutr Biochem 22, 712-722.
204. Cani PD & Delzenne NM (2009) The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 15, 1546-1558.
205. Swartz TD, Duca FA, de Wouters T, et al. (2011) Up-regulation of intestinal type 1 taste receptor 3 and sodium glucose luminal transporter-1 expression and increased sucrose intake in mice lacking gut microbiota. Br J Nutr 107, 621-630.
206. Cani PD, Montoya ML, Neyrinck AM, et al. (2004) Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. Br J Nutr 92, 757-761.
207. Cani PD, Possemiers S, Van de Wiele T, et al. (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58, 1091-1103.
208. Delzenne NM, Cani PD, Daubioul C, et al. (2005) Impact of inulin and oligofructose on gastrointestinal peptides. Br J Nutr 93, Suppl. 1, S157-S161.
209. Wikoff WR, Anfora AT, Liu J, et al. (2009) Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci USA 106, 3698-3703.
210. Cani PD & Delzenne NM (2009) Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. Curr Opin Pharmacol 9, 737-743.
211. Muccioli GG, Naslain D, Backhed F, et al. (2010) The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol 6, 392.
212. Gee JM & Johnson IT (2005) Dietary lactitol fermentation increases circulating peptide YY and glucagon-like peptide-1 in rats and humans. Nutrition 21, 1036-1043.
213. Everard A, Lazarevic V, Derrien M, et al. (2011) Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 60, 2775-2786.
214. Le Poul E, Loison C, Struyf S, et al. (2003) Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 278, 25481-25489.
215. Uribe A, Alam M, Johansson O, et al. (1994) Microflora modulates endocrine cells in the gastrointestinal mucosa of the rat. Gastroenterology 107, 1259-1269.
216. Berthoud HR, Lenard NR & Shin AC (2011) Food reward, hyperphagia, and obesity. Am J Physiol Regul Integr Comp Physiol 300, R1266-R1277.
217. Finlayson G, King N & Blundell JE (2007) Liking vs. wanting food: importance for human appetite control and weight regulation. Neurosci Biobehav Rev 31, 987-1002.
218. Kenny PJ (2010) Reward mechanisms in obesity: new insights and future directions. Neuron 69, 664-679.
219. Stice E, Spoor S, Bohon C, et al. (2008) Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science 322, 449-452.
220. Stice E, Spoor S, Bohon C, et al. (2008) Relation of reward from food intake and anticipated food intake to obesity: a functional magnetic resonance imaging study. J Abnorm Psychol 117, 924-935.
221. Geiger BM, Behr GG, Frank LE, et al. (2008) Evidence for defective mesolimbic dopamine exocytosis in obesityprone rats. FASEB J 22, 2740-2746.
222. Johnson PM & Kenny PJ (2010) Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nat Neurosci 13, 635-641.
223. Stice E, Yokum S, Burger KS, et al. (2011) Youth at risk for obesity show greater activation of striatal and somatosensory regions to food. J Neurosci 31, 4360-4366.
224. Stice E, Yokum S, Bohon C, et al. (2010) Reward circuitry responsivity to food predicts future increases in body mass: moderating effects of DRD2 and DRD4. Neuroimage 50, 1618-1625.
225. Stice E, Yokum S, Blum K, et al. (2010) Weight gain is associated with reduced striatal response to palatable food. J Neurosci 30, 13105-13109.
226. Krugel U, Schraft T, Kittner H, et al. (2003) Basal and feeding-evoked dopamine release in the rat nucleus accumbens is depressed by leptin. Eur J Pharmacol 482, 185-187.
227. Hommel JD, Trinko R, Sears RM, et al. (2006) Leptin receptor signaling in midbrain dopamine neurons regulates feeding. Neuron 51, 801-810.
228. Fulton S, Pissios P, Manchon RP, et al. (2006) Leptin regulation of the mesoaccumbens dopamine pathway. Neuron 51, 811-822.
229. Pfaffly J, Michaelides M, Wang GJ, et al. (2010) Leptin increases striatal dopamine D2 receptor binding in leptindeficient obese (ob/ob) mice. Synapse 64, 503-510.
230. Kim KS, Yoon YR, Lee HJ, et al. (2010) Enhanced hypothalamic leptin signaling in mice lacking dopamine D2 receptors. J Biol Chem 285, 8905-8917.
231. Naleid AM, Grace MK, Cummings DE, et al. (2005) Ghrelin induces feeding in the mesolimbic reward pathway between the ventral tegmental area and the nucleus accumbens. Peptides 26, 2274-2279.
232. Malik S, McGlone F, Bedrossian D, et al. (2008) Ghrelin modulates brain activity in areas that control appetitive behavior. Cell Metab 7, 400-409.